Introduction
Exposure to a variety of viral and bacterial pathogens during pregnancy has been associated with an increased risk of neurodevelopmental or neuropsychiatric disorders in offspring, including schizophrenia (SZ) and autism spectrum disorder (ASD) (Patterson, 2009; Knuesel et al., 2014; Estes and McAllister, 2016) . Maternal immune activation (MIA) studies in pregnant animals indicate that the maternal cytokine response plays a critical role in the subsequent changes in brain and behavioral development of offspring (Meyer, 2014; Boksa, 2010; Meyer et al., 2009; Piontkewitz et al., 2012) . Although early MIA models used live viral or bacterial pathogens to stimulate the maternal immune system (Shi et al., 2003; Fatemi et al., 1998) , more recent efforts have utilized specific immune-activating agents to induce maternal cytokine responses (Smith et al., 2007; Meyer et al., 2005) . One of the most widely used agents in MIA model research is Polyinosinicpolycytidylic acid (PolyIC) (Meyer and Feldon, 2012; Reisinger et al., 2015) . PolyIC is a synthetic analog of double stranded RNA, consisting of a chain of double stranded inosine (I) and cytidine (C), which is detected by toll-like receptor 3 (TLR-3) (Medzhitov, 2001) . Stimulation of these receptors leads to a potent immune response characterized by the production of inflammatory cytokines such as IL-1β, IL-6, TNFα as well as interferons (Alexopoulou et al., 2001; Takeuchi and Akira, 2009 ). During pregnancy, many of these cytokines may cross the placenta and potentially alter neurodevelopment by acting directly on the developing fetus or by indirectly altering placental endocrine or immune function (Deverman and Patterson, 2009; Hsiao and Patterson, 2011; Dahlgren et al., 2006; Zaretsky et al., 2004 ). The MIA model thus provides an experimental system to explore mechanistic links between changes in the maternal-fetal immune environment, altered fetal brain development and emergence of atypical offspring behavior (Carpentier et al., 2013; Lombardo et al., 2018; Arrode-Bruses and Bruses, 2012; O'Loughlin et al., 2017) .
The PolyIC MIA model is used extensively in both mice (Meyer et al., 2006a; Mandal et al., 2011; Hsiao et al., 2013; Malkova et al., 2012) and rats (Zhang et al., 2012; Dickerson et al., 2010; Zuckerman et al., 2003; Crum et al., 2017) , and has recently been adapted for studies in nonhuman primates (Weir et al., 2015; Bauman et al., 2014; Machado et al., 2015; Rose et al., 2017) . In spite of the strong interest in the PolyIC MIA model, methodological variability has yielded inconsistent results, making it increasingly challenging to replicate outcomes and translate results. Given that preclinical research is under increasing pressure to improve reproducibility (Collins and Tabak, 2014; Landis et al., 2012) 
